Dequanter Didier, Shahla Mohammad, Paulus Pascal, Lothaire Philippe H
Department of Surgery, CHU Charleroi (Hopital Andre Vésale), Montigny le Tilleul, Belgium.
Onco Targets Ther. 2012;5:127-31. doi: 10.2147/OTT.S31863. Epub 2012 Jul 27.
With its targeted mechanism of action and synergistic activity with current treatment modalities, cetuximab is a potentially valuable treatment option for patients with recurrent and/or metastatic squamous cell cancer of the head and neck who have progressed on cisplatin-based chemotherapy. The use of cetuximab in combination with radiotherapy as definitive treatment for locoregionally advanced squamous cell cancer of the head and neck is generally restricted to patients unfit to receive cisplatin-based chemoradiation, which is still considered the standard of care. The effect of this epidermal growth factor receptor antagonist occurs without any change in the pattern and the severity of toxicity usually associated with head and neck radiation.
西妥昔单抗具有靶向作用机制，且与现有治疗方式具有协同活性，对于接受基于顺铂的化疗后病情进展的复发性和/或转移性头颈部鳞状细胞癌患者而言，它是一种潜在的有价值的治疗选择。西妥昔单抗联合放疗作为局部晚期头颈部鳞状细胞癌的根治性治疗，通常仅限于不适合接受基于顺铂的放化疗的患者，而基于顺铂的放化疗仍被视为标准治疗方案。这种表皮生长因子受体拮抗剂的作用效果出现时，通常与头颈部放疗相关的毒性模式和严重程度并无任何变化。
